Alternate molecular genetic pathways in ovarian carcinomas of common histological types

被引:85
作者
Willner, Julia
Wurz, Kaitlyn
Allison, Kimberly H.
Galic, Vijaya
Garcia, Rochelle L.
Goff, Barbara A.
Swisher, Elizabeth M. [1 ]
机构
[1] Univ Washington, Dept Obstet & Gynecol, Div Gynecol Oncol, Seattle, WA 98195 USA
[2] Univ Washington, Dept Pathol, Seattle, WA 98195 USA
关键词
ovarian cancer; histology; mutation; p53; PIK3CA;
D O I
10.1016/j.humpath.2006.10.007
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We evaluated alterations in p53, PIK3CA, PTEN, CTNNB1 (beta-catenin), MLH1, and BRAF among common histological Subsets of epithelial ovarian tumors to characterize patterns of alterations of different molecular pathways. There were 12 clear cell, 26 endometrioid, and 51 serous carcinomas evaluated by direct DNA sequencing for mutations in p53, PIK3CA, PTEN, BRAF, and CTNNB1. Methylation-specific polymerase chain reaction (PCR) assessed MLH1 promoter methylation status. Quantitative PCR identified PIK3CA amplification in 22 EC/CC and 94 SC. p53 mutations were identified in 25 (49%) of 51 SC, 11 (42%) of 26 EC, and 1 (8.3%) of 12 CC neoplasms and were more common in grade 3 EC (P =.045) and advanced-stage EC/CC (P =.007). PIK3CA mutations were identified in 3 (25%) of 12 CC, 3 (12%) of 26 EC, and 0 of 51 SC. PTEN mutations were significantly more common in EC (8/26, 31%) compared with CC (0/12; P =.04) and SC (2/51, 4%; P =.002). CTNNB1 mutations were identified, 6 (23%) EC and no CC or SC (P =.008). Both PTEN and CTNNB1 mutations were more common in low-grade EC/CC, whereas PIK3CA mutations occurred only in grade 3 cancers. PTEN and PIK3CA mutations were more common in p53 wild-type tumors (P =.003). PIK3CA amplification occurred in fewer EC/CC (0/22) versus SC (19/94, 20%; P = 0.02) and were slightly more common in p53 wild-type compared with p53 mutant SC (P=.08). Of 26 EC, 22 (85%) had a mutation in one of the genes studied compared with 4 33% of 12 CC (P =.003). Women with EC/CC had significantly better overall survival (P =.0008), and this remained significant after accounting for stage (P =.04). Mutations in p53 or in PTEN/PIK3CA are alternative pathways in ovarian carcinogenesis. Activation of PIK3CA occurs by gene amplification in SC but via somatic mutation of PIK3CA or PTEN in EC and CC. PIK3CA mutations are associated with high-grade tumors, whereas PTEN and CTNNB1 mutations are associated with low-grade tumors. Mutations in p53, PIK3CA, PTEN, and CTNNB1 account for most EC tumors; most CC remain unexplained. EC/CC histology is a favorable prognostic factor. (c) 2007 Published by Elsevier Inc.
引用
收藏
页码:607 / 613
页数:7
相关论文
共 35 条
  • [1] Comparison between primary peritoneal and epithelial ovarian carcinoma: A polpulation-based study
    Barda, G
    Menczer, J
    Chetrit, A
    Lubin, F
    Beck, D
    Piura, B
    Glezerman, M
    Modan, B
    Sadetzki, S
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 190 (04) : 1039 - 1045
  • [2] Ovarian cancer: Changes in patterns at diagnosis and relative survival over the last three decades
    Barnholtz-Sloan, JS
    Schwartz, AG
    Qureshi, F
    Jacques, S
    Malone, J
    Munkarah, AR
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2003, 189 (04) : 1120 - 1127
  • [3] Origins and molecular pathology of ovarian cancer
    Bell, DA
    [J]. MODERN PATHOLOGY, 2005, 18 : S19 - S32
  • [4] Mutation of the PIK3CA gene in ovarian and breast cancer
    Campbell, IG
    Russell, SE
    Choong, DYH
    Montgomery, KG
    Ciavarella, ML
    Hooi, CSF
    Cristiano, BE
    Pearson, RB
    Phillips, WA
    [J]. CANCER RESEARCH, 2004, 64 (21) : 7678 - 7681
  • [5] Molecular genetic alterations in endometrioid carcinomas of the ovary:: Similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas
    Catasús, L
    Bussaglia, E
    Rodríguez, I
    Gallardo, A
    Pons, C
    Irving, JA
    Prat, J
    [J]. HUMAN PATHOLOGY, 2004, 35 (11) : 1360 - 1368
  • [6] Mutations of the BRAF gene in human cancer
    Davies, H
    Bignell, GR
    Cox, C
    Stephens, P
    Edkins, S
    Clegg, S
    Teague, J
    Woffendin, H
    Garnett, MJ
    Bottomley, W
    Davis, N
    Dicks, N
    Ewing, R
    Floyd, Y
    Gray, K
    Hall, S
    Hawes, R
    Hughes, J
    Kosmidou, V
    Menzies, A
    Mould, C
    Parker, A
    Stevens, C
    Watt, S
    Hooper, S
    Wilson, R
    Jayatilake, H
    Gusterson, BA
    Cooper, C
    Shipley, J
    Hargrave, D
    Pritchard-Jones, K
    Maitland, N
    Chenevix-Trench, G
    Riggins, GJ
    Bigner, DD
    Palmieri, G
    Cossu, A
    Flanagan, A
    Nicholson, A
    Ho, JWC
    Leung, SY
    Yuen, ST
    Weber, BL
    Siegler, HF
    Darrow, TL
    Paterson, H
    Marais, R
    Marshall, CJ
    Wooster, R
    [J]. NATURE, 2002, 417 (6892) : 949 - 954
  • [7] Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer
    Dinulescu D.M.
    Ince T.A.
    Quade B.J.
    Shafer S.A.
    Crowley D.
    Jacks T.
    [J]. Nature Medicine, 2005, 11 (1) : 63 - 70
  • [8] hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis
    Esteller, M
    Catasus, L
    Matias-Guiu, X
    Mutter, GL
    Prat, J
    Baylin, SB
    Herman, JG
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (05) : 1767 - 1772
  • [9] PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms
    Freeman, DJ
    Li, AG
    Wei, G
    Li, HH
    Kertesz, N
    Lesche, R
    Whale, AD
    Martinez-Diaz, H
    Rozengurt, N
    Cardiff, RD
    Liu, X
    Wu, H
    [J]. CANCER CELL, 2003, 3 (02) : 117 - 130
  • [10] Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma
    Gemignani, ML
    Schlaerth, AC
    Bogomolniy, F
    Barakat, RR
    Lin, O
    Soslow, R
    Venkatraman, E
    Boyd, J
    [J]. GYNECOLOGIC ONCOLOGY, 2003, 90 (02) : 378 - 381